Effect of Gemcitabine and nab-Paclitaxel with or Without Hydroxychloroquine on Patients with Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial

JAMA Oncology

Volumn 5, Issue 7, 2019, Pages 993-998

  Karasic, Thomas B ^a   O'Hara, Mark H ^a   Loaiza Bonilla, Arturo ^a,b   Reiss, Kim A ^a   Teitelbaum, Ursina R ^a   Borazanci, Erkut ^c   De Jesus Acosta, Ana ^d   Redlinger, Colleen ^a   Burrell, Jessica A ^a   Laheru, Daniel A ^d   Von Hoff, Daniel D ^c,e   Amaravadi, Ravi K ^a   Drebin, Jeffrey A ^a,f   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CANCER TREATMENT CENTERS OF AMERICA   (United States)

^c Virginia G Piper Charitable Trust   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Translational Genomic Research Institute   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; HYDROXYCHLOROQUINE; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; AUTOPHAGY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PENNSYLVANIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; TREND STUDY; UNIVERSITY HOSPITAL; VISUAL DISORDER; CLINICAL TRIAL; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MULTICENTER STUDY; PANCREAS TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; PACLITAXEL; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 85066892253     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2019.0684     Document Type: Article

References (20)

1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014; 371 (11): 1039-1049. doi: 10.1056/NEJMra1404198 25207767
2. Conroy T, Desseigne F, Ychou M,; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364 (19): 1817-1825. doi: 10.1056/NEJMoa1011923 21561347
3. Von Hoff DD, Ervin T, Arena FP, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369 (18): 1691-1703. doi: 10.1056/NEJMoa1304369 24131140
4. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017; 17 (9): 528-542. doi: 10.1038/nrc.2017.53 28751651
5. Amaravadi RK, Yu D, Lum JJ, Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 2007; 117 (2): 326-336. doi: 10.1172/JCI28833 17235397
6. Perera RM, Stoykova S, Nicolay BN, Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature. 2015; 524 (7565): 361-365. doi: 10.1038/nature14587 26168401
7. Yang A, Rajeshkumar NV, Wang X, Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov. 2014; 4 (8): 905-913. doi: 10.1158/2159-8290.CD-14-0362 24875860
8. Yang S, Wang X, Contino G, Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011; 25 (7): 717-729. doi: 10.1101/gad.2016111 21406549
9. O'Hara MH Gallagher M Teitelbaum UR, Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2015; 33 (15-suppl): e15213. doi: 10.1200/jco.2015.33.15-suppl.e15213
10. Eisenhauer EA, Therasse P, Bogaerts J, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45 (2): 228-247. doi: 10.1016/j.ejca.2008.10.026 19097774
11. US Dept of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Published May 28, 2009. Accessed April 22, 2019.
12. Von Hoff DD, Ramanathan RK, Borad MJ, Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011; 29 (34): 4548-4554. doi: 10.1200/JCO.2011.36.5742 21969517
13. O'Hara MH, Karasic TB, Vasilevskaya I, Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer. J Clin Oncol. 2017; 35 (15-suppl): 3545.
14. Miller-Ocuin JL, Bahary NS, Singhi AD, Inhibition of autophagy improves pathologic and biomarker response to preoperative gemcitabine/nab-paclitaxel in potentially resectable pancreatic cancer: a phase II randomized controlled trial. Ann Surg Oncol. 2017; 24: S6-S7.
15. Boone BA, Murthy P, Miller-Ocuin J, Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. BMC Cancer. 2018; 18 (1): 678. doi: 10.1186/s12885-018-4584-2 29929491
16. Rosenfeldt MT, O'Prey J, Morton JP, p53 status determines the role of autophagy in pancreatic tumour development. Nature. 2013; 504 (7479): 296-300. doi: 10.1038/nature12865 24305049
17. Kinsey C, Balakrishnan V, O'Dell MR, Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression. Cell Rep. 2014; 7 (4): 1143-1155. doi: 10.1016/j.celrep.2014.03.061 24794439
18. Yang A, Herter-Sprie G, Zhang H, Autophagy sustains pancreatic cancer growth through both cell-autonomous and nonautonomous mechanisms. Cancer Discov. 2018; 8 (3): 276-287. doi: 10.1158/2159-8290.CD-17-0952 29317452
19. Windon AL, Loaiza-Bonilla A, Jensen CE, Randall M, Morrissette JJD, Shroff SG. A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. J Gastrointest Oncol. 2018; 9 (1): 1-10. doi: 10.21037/jgo.2017.10.14 29564165
20. Kim ST, Lim DH, Jang KT, Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther. 2011; 10 (10): 1993-1999. doi: 10.1158/1535-7163.MCT-11-0269 21862683